Michael B. Cross
Corporate Officer/Principal at SATELLOS BIOSCIENCE INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Gleeson | M | 68 | 6 years | |
| Michael Rudnicki | M | - | 6 years | |
| James L Kirkland | M | - |
AdipoGenix, Inc.
 AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | 27 years |
| Christian Joly | M | - |
Praxim SA
 Praxim SA Medical SpecialtiesHealth Technology Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France. | 16 years |
| Barbara E. Corkey | M | - |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | 27 years |
| Perry B. Molinoff | M | 84 |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Alex MacKenzie | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 years |
| Michael Cross | M | - |
ARTMS, Inc.
 ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | - |
| Paul Schaffer | M | - |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | - |
| Stephen R. Farmer | M | - |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | 27 years |
| Warren Whitehead | M | 71 | 3 years | |
| Freda Miller | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 years |
| George A. Bray | M | - |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | - |
| Robert Korneluk | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 years |
| Elizabeth Williams | F | - | 1 years | |
| Manuel A. Navia | M | 77 |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | - |
| Rima Al-awar | M | - | 3 years | |
| J. Hall | M | - | 4 years | |
| William Jarosz | M | - | - | |
| Ryan Mitchell | M | - | - | |
| Philip Lambert | M | 56 | 2 years | |
| Trudie Resch | F | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 17 years |
| Adam Mostafa | M | 44 | 3 years | |
| P. Thomas Vogel | M | 84 |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | - |
| Kathryn Hayashi | F | - |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | 6 years |
| James Schlosser | M | - |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | - |
| Steven Foster | M | - |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | - |
| Louis P. Lacasse | M | 67 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| George Cipoletti | M | - |
Praxim SA
Praxim SA Medical SpecialtiesHealth Technology Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France. | 14 years |
| Len Ducker | M | - |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | 5 years |
| Guy L. Mayer | M | 72 |
Praxim SA
Praxim SA Medical SpecialtiesHealth Technology Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France. | 10 years |
| Joe Regan | M | 56 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Thomas Francis Gleeson | M | 70 |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | - |
| Brian Bloom | M | 48 | 6 years | |
| Karimah Es Sabar | F | 66 |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | 6 years |
| William Norman Birnie | M | - |
Praxim SA
Praxim SA Medical SpecialtiesHealth Technology Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France. | 14 years |
| John W. Gillard | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Franklin Berger | M | 74 | - | |
| Randal J. Barrett | M | - |
Praxim SA
Praxim SA Medical SpecialtiesHealth Technology Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France. | 14 years |
| William McVicar | M | 66 | - | |
| Serge Langford | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Steve Hochberg | M | 62 |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | - |
| Geoff MacKay | M | 57 | 6 years | |
| Lennie Ryer | M | 64 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Inès Holzbaur | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Courtney Wells | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Punit Dhillon | M | 44 | 12 years | |
| Ronald C. Dela Cruz | M | 48 | 3 years | |
| Veronica Vallejo | F | 51 | 4 years | |
| James Parsons | M | 58 |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 11 years |
| Tu Diep | M | 43 | - | |
| Avtar Dhillon | M | 62 | 12 years | |
| Niclas Stiernholm | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | - |
| Mark A. Witkowski | M | - | - | |
| Anthony Maida | M | 59 | 6 years | |
| Paul M. Goldfarb | M | - | - | |
| James DeMesa | M | 66 | 11 years | |
| Ernest Kitt | M | - | - | |
| Mary A. Mogford | F | 79 | 16 years | |
| Robert W. Luba | M | 81 | - | |
| Mary E. Federau | F | - | - | |
| Richard McKilligan | M | 61 | - | |
| Michael J. Gresser | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 4 years |
| Brian McCluskey | M | - | - | |
| Scott McIntosh | M | - | 17 years | |
| John Dietrich | M | 77 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 6 years |
| Caryn Peterson | F | 65 | - | |
| Michael Berendt | M | 75 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 6 years |
| Sharon Mathers | F | - | - | |
| Gary W. Goertz | M | 71 | 4 years | |
| Kenneth Edward Newport | M | 58 | 3 years | |
| Andreas Wicki | M | 64 | 3 years | |
| Paul S. Anderson | M | 85 | 7 years | |
| Michael G. Moore | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 9 years |
| Henry Y. Pan | M | 77 | 2 years | |
| Nelson M. Sims | M | 76 | 8 years | |
| William Albert Etherington | M | 82 | 10 years | |
| Rocco Marcantonio | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 55 | 70.51% |
| United States | 18 | 23.08% |
| France | 5 | 6.41% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael B. Cross
- Personal Network
